제노레이
Financials
Valuation Metrics
제노레이's Market Cap is ₩445B. At end of 2025 it was ₩605B. Ranked #1786 of 2,405 in KR market (top 74%), #1093 of 1,627 on KOSDAQ (top 67%), #73 of 94 in Health Care Equipment & Services (top 78%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 44.46B KRW | KR#1,786/2,405 Sec#73/94 |
| Revenue | 107.88B KRW | KR#1,373/2,405 Sec#31/94 |
| Net Income | 2.54B KRW | KR#1,370/2,405 Sec#42/94 |
| Total Assets | 138.33B KRW | KR#1,562/2,405 Sec#47/94 |
| Net Assets | 81.05B KRW | KR#1,578/2,405 Sec#45/94 |
| Employees | 358 | KR#676/2,405 Sec#16/94 |
| Value | ||
| P/E | 17.48x | KR#1,158/2,405 Sec#36/94 |
| P/B | 0.55x | KR#966/2,405 Sec#14/94 |
| P/S | 0.41x | KR#848/2,405 Sec#6/94 |
| FCF Yield | 8.90% | KR#685/2,405 Sec#15/94 |
| Profitability | ||
| ROE | 3.14% | KR#1,317/2,405 Sec#44/94 |
| ROA | 1.84% | KR#1,251/2,405 Sec#47/94 |
| Op. Margin | -1.49% | KR#1,709/2,405 Sec#53/94 |
| Revenue Growth | 2.86% | KR#1,325/2,405 Sec#66/94 |
| Financial Health | ||
| Debt Ratio | 70.68% | KR#1,218/2,405 Sec#68/94 |
| Total Debt | 26.39B KRW | KR#1,280/2,405 Sec#34/94 |
| FCF | 3.96B KRW | KR#957/2,405 Sec#26/94 |
| Cash | 14.20B KRW | KR#1,473/2,405 Sec#44/94 |
| Current Ratio | 1.88x | KR#924/2,405 Sec#56/94 |
| Dividend | ||
| Div. Yield | 4.93% | KR#327/2,405 Sec#1/94 |
| Div. Growth | -16.67% | KR—/2,405 Sec—/94 |
| Performance | ||
| 1Y Return | -35.89% | KR#1,586/2,405 Sec#52/94 |
| 1M Return | -8.26% | KR#1,010/2,405 Sec#41/94 |
| From 52W High | -41.81% | KR#823/2,405 Sec#32/94 |
| 1Y MDD | -39.26% | KR#538/2,405 Sec#16/94 |
| Trading | ||
| Volume | 11,619 shares | KR#1,775/2,405 Sec#72/94 |
| Trading Value | 35.6M KRW | KR#1,892/2,405 Sec#77/94 |
| Foreign Own. | 1.95% | KR#1,641/2,405 Sec#60/94 |
| Per Share | ||
| EPS | 175 KRW | KR#1,320/2,405 Sec#40/94 |
| BPS | 5,569 KRW | KR#1,421/2,405 Sec#35/94 |
Company Info
Established in 2001 and listed on KOSDAQ in 2018, the company maintains overseas branches in the United States, Germany, Japan, Türkiye, and China. It researches, develops, manufactures, and sells X-ray diagnostic equipment for hospital and dental medical environments, uniquely operating in both medical and dental sectors domestically. Leveraging its proprietary Complementary Metal-Oxide-Semiconductor Flat Panel Detector (CMOS FPD) sensor development and manufacturing technology, the company achieves cost competitiveness and high quality. It internalizes operations from R&D to sales to meet market demands. Genoray is headquartered in Seongnam-si, Gyeonggi-do.